DYNAGITO trial results of Stiolto Respimat in chronic obstructive pulmonary disease published in The Lancet Respiratory Medicine.- Boehringer.

Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of chronic obstructive pulmonary disease (COPD) patients, comparing Stiolto Respimat (tiotropium bromide and olodaterol), a dual bronchodilator, and Spiriva Respimat (tiotropium bromide) in the reduction of COPD exacerbations, were published in The Lancet Respiratory Medicine. The DYNAGITO study results show that treatment with Stiolto Respimat resulted in a 7 percent lower rate of moderate-to-severe COPD exacerbations compared with Spiriva Respimat alone (p=0.0498), not reaching the targeted significance level (p=0.01) as pre-defined in the study.

The study results also show Stiolto Respimat significantly reduced COPD symptoms and improved health-related quality of life, as measured by the COPD Assessment Test (CAT), compared to Spiriva Respimat. No new side effects or safety concerns were identified in the study, providing additional confirmation in a COPD population at risk for COPD exacerbations, that Stiolto Respimat has a similar safety profile to Spiriva Respimat.

See: "Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial" Peter M A Calverley et al. The Lancet Respiratory Medicine March 28, 2018 online first DOI: https://doi.org/10.1016/S2213-2600(18)30102-4